Eli Lilly’s Retevmo Phase 3 Trial Cuts Recurrence Risk, Boosts 7.46% ETF Stake
Eli Lilly’s Phase 3 LIBRETTO-432 trial for Retevmo enrolled 151 early-stage non-small cell lung cancer patients and showed a highly significant reduction in recurrence or death risk. With a 7.46% weight in Simplify Health Care ETF, this breakthrough could materially boost PINK’s performance.
1. Phase 3 Trial Results
Eli Lilly’s Phase 3 LIBRETTO-432 trial of Retevmo (selpercatinib) enrolled 151 patients with early-stage RET fusion-positive non-small cell lung cancer and demonstrated a highly statistically significant improvement in event-free survival, cutting the risk of recurrence or death compared to placebo. The safety profile was consistent with previous studies, with no new adverse signals reported.
2. Impact on Simplify Health Care ETF
Eli Lilly represents 7.46% of the ETF’s net assets, making the LIBRETTO-432 outcomes a major driver for PINK’s health care exposure; positive efficacy data could spur additional fund inflows and elevate the ETF’s net asset value.
3. Upcoming Data Presentation
Detailed trial results, including subgroup analyses and long-term follow-up, are slated for presentation at an upcoming medical congress, which may further influence investor sentiment and fund allocation decisions.